Investment enhances company s capacity to produce high quality animal health products and reinforces commitment to the community
LINCOLN, Neb.--(BUSINESS WIRE)--Zoetis Inc. today marked the completion of a 19,000-square-foot, three-story expansion at its manufacturing facility in Lincoln, Neb., with a ribbon-cutting ceremony attended by Lincoln Mayor Chris Beutler. Through increased production at the facility, Zoetis is affirming its position as a global leader and world-class manufacturer of high-quality animal health products and an employer of choice in Lincoln.
Zoetis is excited to expand its footprint in Lincoln and provide veterinarians, livestock producers, pet owners and the animals in their care with a reliable, consistent supply of quality animal health products
Zoetis is excited to expand its footprint in Lincoln and provide veterinarians, livestock producers, pet owners and the animals in their care with a reliable, consistent supply of quality animal health products, said Betty Mason, site leader in Lincoln. The entire community can be proud of our expanded manufacturing operations, which enable us to produce 1,200 finished goods for more than 100 markets around the world.
The site is one of the largest internal manufacturing operations within Zoetis, employing approximately 500 people. With the expansion, as many as 30 new positions could be added at peak production time. Zoetis produces some of its flagship pharmaceutical products and vaccines at the Lincoln plant, including BOVI-SHIELD GOLD and RESPISURE ONE for livestock and RIMADYL (carprofen) for dogs. The expansion will also facilitate the full production of SYNOVEX, a product that helps increase weight gain and improve feed efficiency in beef cattle.
Zoetis most recent achievements in Lincoln include the manufacturing of two products that address unmet market needs and help improve veterinarians approach to prevention and treatment. These products include Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy that targets interleukin-31 (IL-31) to help reduce clinical signs associated with atopic dermatitis in dogs, as well as a vaccine to help fight porcine epidemic diarrhea virus (PEDv)*, an emerging disease that devastated U.S. pig farms in recent years. Both products are conditionally licensed by the U.S. Department of Agriculture.
Zoetis and its predecessors have long maintained a presence in the Lincoln area. In the early 20th century, pharmaceutical firms and distributors such as Norden Laboratories established facilities in Nebraska that evolved over time. More recent incarnations of these animal health companies, including Zoetis, have continued to play an important economic role in the Lincoln community.
IMPORTANT SAFETY INFORMATION: As a class, NSAIDS may be associated with gastrointestinal, kidney and liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including RIMADYL. Use with other NSAIDS or corticosteroids should be avoided.
IMPORTANT SAFETY INFORMATION: Do not use SYNOVEX products in veal calves. Refer to label for complete directions for use, precautions, and warnings.
* This product license is conditional. Safety and efficacy studies are in progress.
Zoetis (zo-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com.
For a Complete Version of this BUSINESS WIRE Press Release